Immatics NV
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Immatics NV.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 7.90 $ to 11.90 $ · Last price: 8.50 $ (As of: September 28, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/29/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Immatics NV IMTX | 1.2 | – | 7.2 | -423.7 | -867.9 | -69.0 | 10.4 |
| Vertex Pharmaceuticals Inc VRTX | 133.5 | 32.0 | 24.4 | 55.0 | 38.1 | 9.6 | 36.8 |
| Moderna Inc MRNA | 78.3 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| Regeneron Pharmaceuticals Inc REGN | 78.2 | 18.9 | 13.5 | 44.5 | 20.7 | 1.0 | 34.1 |
| argenx NV ARGX | 60.5 | 37.2 | 30.7 | 59.1 | 32.0 | 89.6 | 36.6 |
| Revolution Medicines Inc RVMD | 41.9 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.3 |
| BeiGene, Ltd. ONC | 41.5 | 65.5 | 32.4 | 88.9 | 19.1 | 40.2 | 12.6 |
| Alnylam Pharmaceuticals Inc ALNY | 33.9 | 64.3 | 28.6 | 79.7 | 23.0 | 65.2 | -42.8 |
| Royalty Pharma Plc RPRX | 32.2 | 31.5 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 41.9 | 34.6 | 19.2 | 55.0 | 20.7 | 5.1 | 36.6 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year €M
Revenue Operating income Net income
| Fiscal Year | Revenue (€M) | EBIT (€M) | Net Income (€M) | EPS (€) | Operating Cash Flow (€M) | Equity (€M) | Total Assets (€M) |
|---|---|---|---|---|---|---|---|
| 2018 | 4 | -34 | -31 | -0.50 | 21 | -10 | 61 |
| 2019 | 18 | -33 | -32 | -0.50 | 71 | -42 | 134 |
| 2020 | 31 | -70 | -211 | -4.40 | -86 | 87 | 255 |
| 2021 | 35 | -86 | -93 | -1.48 | -82 | 24 | 175 |
| 2022 | 173 | 30 | 28 | 0.41 | 100 | 203 | 408 |
| 2023 | 54 | -102 | -95 | -1.18 | 18 | 218 | 510 |
| 2024 | 156 | -39 | 15 | 0.14 | -158 | 575 | 696 |
| 2025 | 48 | -182 | -196 | -1.61 | -170 | 484 | 562 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales (€M) | Sales YoY (%) | Net Margin (%) | OCF (€M) | FCF (€M) |
|---|---|---|---|---|---|---|---|
| 2024: Q2 | -0.19 | 45.70 | 19 | -16.10 | -96.10 | -33 | -36 |
| 2024: Q3 | -0.08 | 76.50 | 51 | 753.20 | -17.00 | -34 | -37 |
| 2024: Q4 | 0.45 | 251.00 | 56 | 253.30 | 79.80 | -59 | -60 |
| 2025: Q1 | -0.37 | -1,133.30 | 19 | -39.00 | -214.50 | -34 | -37 |
| 2025: Q2 | -0.68 | -257.90 | 5 | -74.70 | -1,485.10 | -39 | -41 |
| 2025: Q3 | -0.49 | -512.50 | 5 | -89.70 | -974.50 | -45 | -46 |
| 2025: Q4 | -0.34 | -174.50 | 20 | -64.90 | -180.60 | -58 | -59 |
| 2026: Q1 | -0.51 | -37.80 | 8 | -59.00 | -759.50 | -43 | -44 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Growth
Quality & Balance Sheet
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate (€) | EPS Range (€) | Revenue Estimate (€M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -2.07 | -2.35 – -1.91 | 47 | -10.5% | 7 |
| 12/31/2027 | -2.07 | -2.46 – -1.63 | 40 | 0.1% | 7 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -34.6%
- More than 10% revenue growth is expected for the coming year -75.4%
- Share count grows by less than 3% a year 21.5%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -433.6%
- Gross margin at 40% or higher and without meaningful erosion 100.0%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA 454 m net cash
- Operating cash flow covers the profits of the last three years -34 m
- Return on capital at 15% or higher, or up versus two years ago -35.1%
- Insiders hold at least 10% or are net buyers 17.6%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
2/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 43.9%
- Exp. sales growth 3Y > 5% -9.4%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -9.4%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 1
- Max. EBIT decline < 50% 100.0%
- Return on equity > 15% -40.7%
- ROCE > 15% -35.1%
- Expected return > 10% -25.1%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | Perceptive Advisors Llc | Director | Buy | 863,060 | 8.69 | 7,499,991 |
The company
About the Company
Immatics N.V. ist ein klinisches biopharmazeutisches Unternehmen, das sich auf die Erforschung und Entwicklung potenzieller T-Zell-umleitender Immuntherapien zur Behandlung von Krebs in den Vereinigten Staaten konzentriert. Das Unternehmen entwickelt zielgerichtete Immuntherapien mit Fokus auf die Behandlung solider Tumoren durch zwei unterschiedliche Behandlungsansätze: adoptive Zelltherapien (ACT) und antikörperähnliche TCR-Bispezifische. Die Produktpipeline umfasst Anzu-cel (IMA203), eine einmalig verabreichte PRAME-Zelltherapie, die sich in Phase 2 befindet; IMA203CD8, ein Zelltherapieprodukt in klinischer Phase 1; IMA204, das auf das Tumorstroma abzielt und sich in klinischer Phase 1 befindet; sowie Anzu-cel in Kombination mit Modernas PRAME-Zelltherapie-Verstärker (mRNA-4203), der sich in klinischer Phase 1 befindet. Das Unternehmen entwickelt außerdem TCR-Bispezifische Produkte, darunter IMA401 und IMA402, die sich in klinischer Phase 1a befinden. Das Unternehmen unterhält eine strategische Kooperationsvereinbarung mit dem MD Anderson Cancer Center zur Entwicklung mehrerer T-Zell- und TCR-basierter adoptiver Zelltherapien, mit der Celgene Corporation zur Entwicklung neuartiger adoptiver Zelltherapien gegen verschiedene Krebsarten sowie mit Genmab A/S zur Entwicklung T-Zell-bindender bispezifischer Immuntherapien gegen verschiedene Krebsindikationen. Immatics N.V. hat ihren Hauptsitz in Tübingen, Deutschland.
- Employees
- 704
- Headquarters
- Tübingen, Germany
- Address
- Paul-Ehrlich-Strasse 15-19, 72076 Tübingen, Germany
- Phone
- 49 7071 5397 0
- Website
- immatics.com
- IPO Date
- 07/02/2020
- ISIN
- NL0015285941
Management
| Name | Title | Birth Year |
|---|---|---|
| Harpreet Singh Ph.D. | CEO, MD, Member of Management Board & Executive Director | 1975 |
| Venkat Ramanan Ph.D. | Chief Financial Officer | 1970 |
| Amie Krause | Chief People Officer | 1973 |
| Hans-Georg Rammensee Ph.D. | Co-Founder & Member of the Scientific Advisory Board | – |
| Toni Weinschenk Ph.D. | Co-Founder & Chief Innovation Officer | 1970 |
| Steffen Walter Ph.D. | Chief Operations Officer | 1977 |
| Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting & Accounting | – |
| James Pepin J.D. | General Counsel & Corporate Secretary | – |
| Lauren Schroeder | Vice President of Marketing | – |
| Carsten Reinhardt M.D., Ph.D. | Chief Development Officer | 1967 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.